These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11267168)

  • 21. Induction with basiliximab in renal transplantation.
    Ferrer F; Machado S; Alves R; Macário F; Bastos C; Roseiro A; Mota A
    Transplant Proc; 2010 Mar; 42(2):467-70. PubMed ID: 20304166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
    Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract]   [Full Text] [Related]  

  • 23. Early steroid withdrawal protocol using basiliximab in kidney transplantation.
    Teraoka S; Sato S; Kai K; Kawase T; Nakamura M; Tojinbara T; Nakajima I; Fuchinoue S
    Transplant Proc; 2004 Mar; 36(2 Suppl):478S-482S. PubMed ID: 15041392
    [No Abstract]   [Full Text] [Related]  

  • 24. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients.
    Oh CK; Kim SJ; Kim JH; Lee JH
    J Korean Med Sci; 2012 Apr; 27(4):337-42. PubMed ID: 22468094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol.
    Rahamimov R; Yussim A; After T; Lustig S; Bar-Nathan N; Shaharabani E; Shapira Z; Shabthai E; Mor E
    Transplant Proc; 2003 Mar; 35(2):653-4. PubMed ID: 12644082
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
    Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
    Höcker B; John U; Plank C; Wühl E; Weber LT; Misselwitz J; Rascher W; Mehls O; Tönshoff B
    Transplantation; 2004 Jul; 78(2):228-34. PubMed ID: 15280683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.
    Keown P; Balshaw R; Khorasheh S; Chong M; Marra C; Kalo Z; Korn A
    BioDrugs; 2003; 17(4):271-9. PubMed ID: 12899644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of basiliximab induction therapy in ABO-incompatible kidney transplantation: a rapid steroid withdrawal protocol.
    Ando T; Tojimbara T; Sato S; Nakamura M; Kawase T; Kai K; Nakajima I; Fuchinoue S; Teraoka S
    Transplant Proc; 2004 Sep; 36(7):2182-3. PubMed ID: 15518793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO
    Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract]   [Full Text] [Related]  

  • 35. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil.
    Höcker B; Weber LT; Feneberg R; Drube J; John U; Fehrenbach H; Pohl M; Zimmering M; Fründ S; Klaus G; Wühl E; Tönshoff B
    Transplantation; 2009 Mar; 87(6):934-41. PubMed ID: 19300199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.
    Balbontin F; Kiberd B; Fraser A; Kiberd M; Lawen J
    Clin Transplant; 2005 Apr; 19(2):225-9. PubMed ID: 15740559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing acute rejection with basiliximab and triple immunosuppression after renal transplantation.
    Kandus A
    Transplant Proc; 2002 Nov; 34(7):2907-9. PubMed ID: 12431653
    [No Abstract]   [Full Text] [Related]  

  • 39. Mycophenolate mofetil in living donor renal allograft recipients.
    Park K; Moon JI; Kim SI; Kim YS
    Transplant Proc; 1999; 31(1-2):1133. PubMed ID: 10083506
    [No Abstract]   [Full Text] [Related]  

  • 40. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
    Wiesel M; Carl S
    J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.